What is Deka Biosciences?
Headquartered in Germantown, Maryland, Deka Biosciences is a clinical-stage biotechnology company dedicated to the development of innovative therapies for cancer and inflammatory diseases. The company utilizes a proprietary platform designed to optimize the delivery of cytokines, aiming to enhance therapeutic efficacy while minimizing systemic toxicity. By focusing on precision medicine, Deka Biosciences addresses critical gaps in current treatment paradigms, positioning itself as a key player in the evolving landscape of targeted immunotherapy. Its market position is bolstered by a commitment to rigorous scientific validation and a clear focus on patient-centric outcomes, which has attracted significant interest from both corporate and venture capital entities.
How much funding has Deka Biosciences raised?
Deka Biosciences has raised a total of $40M across 2 funding rounds:
Series A
$20M
Series B
$20M
Series A (2021): $20M with participation from Bayer
Series B (2023): $20M led by MPM BioImpact and Lumira Ventures
Key Investors in Deka Biosciences
Bayer
Bayer is a global enterprise in the life science fields of healthcare and nutrition, focusing on pharmaceuticals and consumer health to address the challenges of an aging population.
MPM BioImpact
MPM BioImpact manages early-stage venture funds and impact funds, specializing in converting complex scientific research into viable therapeutic solutions for patients.
Lumira Ventures
Lumira Ventures is a prominent life sciences venture capital firm that partners with mission-driven entrepreneurs to commercialize impactful healthcare innovations across North America.
What's next for Deka Biosciences?
With the recent infusion of capital, Deka Biosciences is poised to transition into a more advanced phase of clinical development. The strategic roadmap likely involves scaling its manufacturing capabilities and expanding its clinical trial footprint to evaluate the safety and efficacy of its lead candidates in broader patient populations. As the company moves forward, the focus will remain on achieving key regulatory milestones and potentially exploring strategic partnerships to facilitate the commercialization of its therapeutic assets. The backing from established life science investors provides not only the necessary financial runway but also the operational expertise required to navigate the complex regulatory and competitive environment of the global biotech market.
See full Deka Biosciences company page
